{"id":1940,"date":"2025-12-03T13:38:44","date_gmt":"2025-12-03T13:38:44","guid":{"rendered":"https:\/\/www.chromacon.com\/?post_type=application&p=1940"},"modified":"2026-05-12T14:28:58","modified_gmt":"2026-05-12T12:28:58","slug":"peptides","status":"publish","type":"application","link":"https:\/\/www.chromacon.com\/en\/applications\/peptides\/","title":{"rendered":"Peptides"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

\n PEPTIDES <\/p>\n \n

\n More Peptide<\/strong>. Fewer IPCs.
\nContinuous Polishing Chromatography with MCSGP.\n <\/h1>\n \n
\n

Higher yield, less solvent, no re-chromatography \u2014 no purity\u2013yield trade-off. MCSGP is the twin-column preparative HPLC process proven at commercial scale by Bachem on Bivalirudin.<\/p>\n

 <\/p>\n

Across 4 PPQ runs: 99.2%<\/strong> Purity | \u221296%<\/strong> In-process controls | Multi-day<\/strong> GMP campaigns | +9%<\/strong> Yield gain<\/p>\n

 <\/p>\n

Source: Eisenhuth & M\u00fcller-Sp\u00e4th, Processes 2025 (Bachem Bivalirudin PPQ campaign, Open Access)<\/em><\/strong><\/p>\n <\/div>\n <\/div>\n\n

\n
\n Talk to Our Peptide Specialists<\/span><\/a><\/span> <\/div>\n
\n Download the PPQ Paper<\/span><\/a><\/span> <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
\n
\n
\n \"\" <\/div>\n\n \n
\n
\n Talk to Our Peptide Specialists<\/span><\/a><\/span> <\/div>\n
\n Download the PPQ Paper<\/span><\/a><\/span> <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n
\n \n
\n
\n
\n

\n The Peptide Purification Bottleneck <\/h2>\n \n
\n

Peptide demand is surging \u2014 driven by GLP-1 agonists, oncology peptides, and a pipeline of 150+ candidates in clinical trials. Purification by reversed-phase HPLC is the critical bottleneck.<\/p>\n

Conventional batch chromatography forces a painful trade-off: high purity or high yield \u2014 not both.<\/strong> Achieving target purity requires a narrow center-cut, discarding valuable product in side-fractions. Recovering that product means costly re-chromatography \u2014 with all the associated solvent consumption, QC testing, and campaign delays.<\/p>\n

For high-volume APIs like semaglutide and tirzepatide, this inefficiency is unsustainable.<\/p>\n <\/div>\n \n <\/div>\n\n

\n \"\" \n <\/div>\n <\/div>\n <\/section>\n\n<\/section>\n\n
\n \n
\n
\n
\n

\n The Solution: MCSGP with AutoPeak\u00ae for Peptide Purification <\/h2>\n \n
\n

MCSGP (Multi-column Countercurrent Solvent Gradient Purification) eliminates the purity-yield trade-off in peptide chromatography. Two identical columns continuously recycle impure side-fractions \u2014 recovering peptide product that batch processes discard. It uses the same RP and IEX resins and solvents<\/strong> as your existing batch peptide method.<\/p>\n

AutoPeak\u00ae dynamic process control monitors peptide elution profiles in real-time via UV and conductivity, automatically adjusting collection windows to maintain consistent output quality \u2014 enabling robust, unattended 24\/7 peptide purification.<\/p>\n

\n

Same chemistry. Better results.<\/strong> MCSGP works with the RP-C18, C8, C4, IEX, and mixed-mode stationary phases and mobile phases already used in your peptide batch process \u2014 your existing resin and solvent conditions are the starting point for MCSGP development. No change to your chromatographic chemistry is needed.<\/p>\n<\/blockquote>\n <\/div>\n \n Learn About MCSGP + AutoPeak\u00ae<\/span><\/a><\/span> <\/div>\n\n

\n \"\" \n <\/div>\n <\/div>\n <\/section>\n\n<\/div><\/section>\n\n\n

Proven Results: MCSGP vs. Batch – Peptide Purification<\/h2>\n\n\n\n
\n
\n
\n \n \n
\n \n

\n +10\u201350% <\/h2>\n \n

\n Yield Increase <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 30-75% \u2193 <\/h2>\n \n

\n Solvent Reduction <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 80% \u2193 <\/h2>\n \n

\n Campaign Time <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n<\/div>\n\n\n\n

\n
\n
\n \n \n
\n \n

\n Zero <\/h2>\n \n

\n Re-chromatography Runs <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 75\u201395% \u2193 <\/h2>\n \n

\n Fewer IPC Analyses <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n\n\n\n

\n
\n \n \n
\n \n

\n 50% \u2193 <\/h2>\n \n

\n Lyophilization Volume <\/p>\n \n \n <\/div>\n\n<\/div>\n\n <\/div><\/section><\/div>\n<\/div>\n\n\n

\n \n
\n \n